From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotics

SG Wicha, A.G. Märtson, E.I. Nielsen, B.C.P. Koch, L.E. Friberg, J.W. Alffenaar, I.K. Minichmayr
Clinical Pharmacology & Therapeutics, 109, 928-941 (2021).

Please login to see attachment

International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).

BT Tsuji, JM Pegue, AP Zavascki, M Paul, GL Daikos, A Forrest, DR Giacobbe, C Viscoli, H Giamarellou, I Karaiskos, D Kaye, JW Mouton, VH Tam, C Thamlikitkul, RG Wunderink, J Li, RL Nation, KS Kaye
Pharmacotherapy, 39, 10-39 (2019).

Please login to see attachment

Concentration-dependent plasma protein binding: Expect the unexpected

RL Nation, U Theuretzbacher, BT Tsuji, on behalf of the International Society of Anti-Infective Pharmacology (ISAP)
European Journal of Pharmaceutical Sciences, 122, 341-346 (2018).

Please login to see attachment

Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus: RL Nation, J Li, O. Cars, W. Couet, MN Dudley, KS Kaye, JW Mouton, DL Paterson, VH Tam, U. Theuretzbacher, BT Tsuji, JD Turnidge.
The Lancet Infectious Diseases, Early Online Publication, 21 October 2014

Please login to see attachment